NCT07521722Not yet recruiting
DIV-AD BARCELONA: Alzheimer's Blood-Based Biomakers for a Diverse Community
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
The DIV-AD study aims to find out whether levels of Alzheimer's disease markers in blood differ among the main ethnical groups living in central Barcelona. It will also examine how factors such as age, income, education, and health conditions may affect these levels. In addition, the study will identify barriers that may make it difficult to use these blood tests in primary care. The final goal is to help ensure that everyone in Barcelona has fair access to early prevention strategies for Alzheimer's disease.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 250 (estimated)
- First submitted
- 30 Mar 2026
- Start date
- 27 Apr 2026
- Primary completion date
- 27 Apr 2027
- Lead sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
- Diseases
- Alzheimer disease
- NCT number
- NCT07521722
What you commit to
- Study type: Observational
- Planned participants: 250
- From 27 Apr 2026 to the primary completion date, 27 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Individuals with cognitive complaints and who have sought for medical help for cognitive impairment at any time in their life
- Patients with relevant medical illnesses that may significantly interfere with the interpretation of results. This includes auditory and visual perception disorders, active oncological disease under treatment (localized tumors are excluded) and any condition that, in the investigator's opinion, may interfere with the correct performance/interpretation of the study procedures and/or with future permanence in the study.
- Major psychiatric disorders (according to the DSM-V manual) or diseases that affect cognitive abilities (major depressive episode, bipolar disorder, schizophrenia, etc).
- Acquired brain damage: history of head trauma with macroscopic parenchymal or non-axial lesion, large-vessel ischemic or hemorrhagic stroke, brain tumours and any other etiologies that can cause acquired brain damage (i.e., chemotherapy or brain radiotherapy).
- Parkinson's disease, epilepsy under treatment and with frequent seizures (\> 1/month) in the last year, multiple sclerosis or other neurodegenerative diseases.
Other
- Cognitive decline defined by CDR\>0.
Who the study is looking for
- Cognitively Unimpaired individuals aged between 50 and 75 years at the time of signing the informed consent
- Individuals interested in participating, able to follow study procedures, and who understand that all the tests are carried out in a research context.
- Explicit desire to participate in the tests and procedures of the study, including: collection of study variables, cognitive and neurologic assessment, blood sampling.
- Signing the informed consent, agreeing not to receive the research results that will not be of no clinical interest for the participant.
Age in the registry: 50 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| BarcelonaBeta Brain Research Center - EAP Raval Sud Coordinator of this site? Confirm its status | Barcelona | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.